name,target,sequence,cdr1,cdr2,cdr3,pdb_id,affinity_nM,source,reference
Trastuzumab,HER2,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,GFNIKDTYIH,IYPTNGYTRYADSVKG,SRWGGDGFYAMDYW,1N8Z,0.1,Therapeutic,"Nature 2003, 421(6924):756-760"
Pertuzumab,HER2,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGKGLEWMGWINPNSGGTNYAQKFQGRVTMTTDTSTSTVYMELSSLRSEDTAVYYCARDYWGQGTLVTVSS,GYTFTDYYMH,WINPNSGGTNYAQKFQG,ARDYW,1S78,0.5,Therapeutic,"Cancer Cell 2004, 5(4):317-328"
Margetuximab,HER2,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGNYGMDVWGQGTLVTVSS,GFTFSSYAMS,SISGSGGSTYYADSVKG,RDRGNYGMDVW,6BGY,0.3,Therapeutic,"JCO 2019, 37(15_suppl):1000"
